1. Integrated pipeline: high speed and high throughput instrument’s rigid demand of high-end hospitals and laboratories will develop towards the direction of integrated pipeline to meet high-end hospitals’ test requ..

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note.

Several leading In Vitro Diagnostic (IVD) companies have posted their first-quarter results for 2026, showing mixed performance across revenue, profitability, and cash flow.

Original from: bioMérieux - First quarter was impacted by mild respiratory epidemiology, and by the uncertain geopolitical and macroeconomic environment which drives softness in customers’investment de..

Rapigen, Inc., an in vitro diagnostics company specializing in rapid diagnostic tests, announced that three of its malaria rapid diagnostic tests (RDTs) — BIOCREDIT Malaria Ag Pf (pLDH), BIOCREDIT Malaria Ag Pf (pLDH/HRPII), and BIOCREDIT Malaria Ag Pf/Pv (pLDH/pLDH) — were officially added to the World Health Organization (WHO) Prequalification (PQ) product list on April 14, 2025.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026.

Original from: Roche - Group sales were +6% at constant exchange rates (CER), -5% when reported in CHF and +9% in USD, in the first three months, driven by high demand for our innovative medicines and di..

Artera, a developer of multimodal AI-based prognostic and predictive cancer tests, announced today that it was granted CE marking under the European Union In Vitro Diagnostic Regulation (EU IVDR) for both its ArteraAI Prostate Biopsy Assay and ArteraAI Breast Cancer Assay, marking a major step in the company’s global expansion.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Google Cloud today announced a landmark partnership to enhance Merck’s digital backbone as an AI-enabled enterprise. This multi-year investment, valued at up to $1 billion, will deploy an agentic platform across Merck’s research & development (R&D), manufacturing, commercial, and corporate functions – and includes Google Cloud engineers working alongside Merck teams to deploy Google Cloud’s most sophisticated AI, including Gemini Enterprise.

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2026.

Danaher Corporation (NYSE: DHR) today announced results for the first quarter 2026. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.

3.2.2 Future Development Trend of Blood Typing Instruments It can be seen from analysis on major blood grouping analyzer-related patent applications published in the 3 years from 2018 to 2021 that benefited from..

Boehringer Ingelheim has launched a new artificial intelligence (AI) and machine learning (ML) centre in London, representing the company’s latest move to drive improved patient outcomes through the technologies’ application.

QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today it has completed the acquisition of LEX Diagnostics ("LEX") for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration ("FDA") 510(k) clearance and CLIA waiver in February 2026.